Abstract
The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active anti-retroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 271-272 |
| Number of pages | 2 |
| Journal | Orthopedics |
| Volume | 24 |
| Issue number | 3 |
| Publication status | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Orthopedics and Sports Medicine
Cite this
Osteonecrosis in protease inhibitor-treated patients. / Bonfanti, P.; Gabbuti, A.; Carradori, S.; Pusterla, L.; Parazzini, F.; Landonio, S.; Quirino, T.
In: Orthopedics, Vol. 24, No. 3, 2001, p. 271-272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Osteonecrosis in protease inhibitor-treated patients
AU - Bonfanti, P.
AU - Gabbuti, A.
AU - Carradori, S.
AU - Pusterla, L.
AU - Parazzini, F.
AU - Landonio, S.
AU - Quirino, T.
PY - 2001
Y1 - 2001
N2 - The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active anti-retroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.
AB - The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active anti-retroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.
UR - http://www.scopus.com/inward/record.url?scp=0035079224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035079224&partnerID=8YFLogxK
M3 - Article
VL - 24
SP - 271
EP - 272
JO - Orthopedics
JF - Orthopedics
SN - 0147-7447
IS - 3
ER -